102 related articles for article (PubMed ID: 26596829)
1. Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells.
Yahya SM; Hamed AR; Emara M; Soltan MM; Abd-Ellatef GE; Abdelnasser SM
Tumour Biol; 2016 May; 37(5):5925-32. PubMed ID: 26596829
[TBL] [Abstract][Full Text] [Related]
2. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.
Zhang DM; Li YJ; Shu C; Ruan ZX; Chen WM; Yiu A; Peng YH; Wang J; Lan P; Yao Z; Fung KP; Fu LW; Chen ZS; Ye WC
Anticancer Drugs; 2013 Jun; 24(5):441-54. PubMed ID: 23466650
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Ye P; Xing H; Lou F; Wang K; Pan Q; Zhou X; Gong L; Li D
Cancer Chemother Pharmacol; 2016 Mar; 77(3):613-21. PubMed ID: 26846508
[TBL] [Abstract][Full Text] [Related]
4. Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells.
Liu DL; Li YJ; Yao N; Xu J; Chen ZS; Yiu A; Zhang CX; Ye WC; Zhang DM
Eur J Pharmacol; 2014 Jun; 733():34-44. PubMed ID: 24704556
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression.
Zhou JJ; Deng XG; He XY; Zhou Y; Yu M; Gao WC; Zeng B; Zhou QB; Li ZH; Chen RF
Int J Oncol; 2014 Jun; 44(6):2034-40. PubMed ID: 24647772
[TBL] [Abstract][Full Text] [Related]
6. ABCB1, ABCC1, and LRP gene expressions are altered by LDL, HDL, and serum deprivation in a human doxorubicin-resistant uterine sarcoma cell line.
Celestino AT; Levy D; Maria Ruiz JL; Bydlowski SP
Biochem Biophys Res Commun; 2015 Feb; 457(4):664-8. PubMed ID: 25603048
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.
Shi Y; Wang SY; Yao M; Sai WL; Wu W; Yang JL; Cai Y; Zheng WJ; Yao DF
World J Gastroenterol; 2015 Dec; 21(45):12814-21. PubMed ID: 26668505
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
Zaja R; Caminada D; Loncar J; Fent K; Smital T
Toxicol Appl Pharmacol; 2008 Mar; 227(2):207-18. PubMed ID: 18076962
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells.
Wang F; Chen Y; Huang L; Liu T; Huang Y; Zhao J; Wang X; Yang K; Ma S; Huang L; To KK; Gu Y; Fu L
Oncotarget; 2015 Dec; 6(38):40850-65. PubMed ID: 26506420
[TBL] [Abstract][Full Text] [Related]
10. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
Xu P; Jiang YF; Wang JH
Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
[TBL] [Abstract][Full Text] [Related]
11. NRF2/ABCB1-mediated efflux and PARP1-mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells.
Xia X; Wang Q; Ye T; Liu Y; Liu D; Song S; Zheng C
Fundam Clin Pharmacol; 2020 Feb; 34(1):41-50. PubMed ID: 31420991
[TBL] [Abstract][Full Text] [Related]
12. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
Zhou Z; Wan L; Han Y; Meng X; Yang Q; Li Y; Yu Q; Shen Z; Guo C
Pharm Biol; 2013 Aug; 51(8):968-73. PubMed ID: 23735077
[TBL] [Abstract][Full Text] [Related]
13. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.
Yang T; Zheng ZM; Li XN; Li ZF; Wang Y; Geng YF; Bai L; Zhang XB
Exp Biol Med (Maywood); 2013 Sep; 238(9):1024-32. PubMed ID: 23925649
[TBL] [Abstract][Full Text] [Related]
14. Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Dragoj M; Milosevic Z; Bankovic J; Tanic N; Pesic M; Stankovic T
Cell Oncol (Dordr); 2017 Feb; 40(1):47-62. PubMed ID: 27822706
[TBL] [Abstract][Full Text] [Related]
15. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.
Tang SJ; Chen LK; Wang F; Zhang YK; Huang ZC; To KK; Wang XK; Talele TT; Chen ZS; Chen WQ; Fu LW
Biochem Pharmacol; 2014 Sep; 91(2):144-56. PubMed ID: 25058526
[TBL] [Abstract][Full Text] [Related]
16. Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1.
Lee WK; Chakraborty PK; Thévenod F
Int J Cancer; 2013 Aug; 133(3):556-67. PubMed ID: 23354914
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
18. Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1.
Ma J; Wang T; Guo R; Yang X; Yin J; Yu J; Xiang Q; Pan X; Tang H; Lei X
J Drug Target; 2015; 23(6):519-24. PubMed ID: 25714665
[TBL] [Abstract][Full Text] [Related]
19. Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells.
Ma W; Feng S; Yao X; Yuan Z; Liu L; Xie Y
Sci Rep; 2015 Dec; 5():18789. PubMed ID: 26689156
[TBL] [Abstract][Full Text] [Related]
20. [Small interfering RNA targeting STAT3 enhances antitumor activity of doxorubicin].
Wang TX; Wang YY; Zhang ZQ
Yao Xue Xue Bao; 2013 Jan; 48(1):52-8. PubMed ID: 23600141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
